Vendor To Visionary: Transforming AAV Manufacturing

By Artur Padzik, 3PBIOVIAN

Traditional transactional CDMO partnerships, while functional for simpler programs, often fail to meet the intricate demands of AAV development. These commodity-based relationships prioritize cost over innovation, frequently leading to technical pitfalls, communication bottlenecks, and expensive troubleshooting during scale-up. Conversely, establishing a collaborative partnership at the proof-of-concept stage allows sponsors to leverage a CDMO’s deep expertise in risk management and process alignment.

By engaging experts early, developers can optimize molecular designs for manufacturability and identify critical process parameters using scale-down models. This foresight prevents costly process rebuilding and mitigates supply chain risks by securing essential raw materials ahead of time. Utilizing a flexible platform process further enhances efficiency, delivering superior vector yield and stability while ensuring regulatory compliance.

Ultimately, moving beyond a transactional mindset toward integrated collaboration provides drug developers with predictive costs, streamlined timelines, and a more robust, clinically viable product that is prepared for the complexities of commercial scaling.